References
- 1. Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz. Gastroenterol. 2019; 14(1): 26–38.
- 2. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
- 3. Degiuli M, De Manzoni G, Di Leo A et al. Gastric cancer: Current status of lymph node dissection. World J Gastroenterol 2016 March 14; 22(10): 2875-2893.
- 4. Vasilescu C, Trandafir B. Probleme de chirurgie oncologică. Lecția japoneză. Limfadenectomia D2 în cancerul gastric. Chirurgia (2011) 106: 163-170
- 5. Giuliani A, Miccini M, Basso L. Extent of lymphadenectomy and perioperative therapies: two open issues in gastric cancer. World J Gastroenterol 2014; 20: 3889-3904.
- 6. Jiang L, Yang KH, Chen Y et al. Systematic review and meta-analysis of the effectiveness and safety of extended lymphadenectomy in patients with resectable gastric cancer. Br J Surg 2014.
- 7. Verlato G, Giacopuzzi S, Bencivenga M et al. Problems faced by evidence-based medicine in evaluating lymphadenectomy for gastric cancer. World J Gastroenterol 2014; 20: 12883-12891.
- 8. Songun I, Putter H, Kranenbarg EM et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010; 11: 439-449.
- 9. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Shia LT, Whang-Peng J. Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer. Br J Surg 2004; 91: 283-287.
- 10. Wu CW, Hsiung CA, Lo SS et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 2006; 7: 309-315.
- 11. Seevaratnam R, Bocicariu A, Cardoso R et al. A meta-analysis of D1 versus D2 lymph node dissection. Gastric Cancer 2012; 15 Suppl 1: S60-S69.
- 12. Degiuli M, Sasako M, Ponti A. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg 2010; 97: 643-649.
- 13. Japanese gastric cancer treatment guidelines 2018 (5th edition). Japanese Gastric Cancer Association. Gastric Cancer 2020; https://doi.org/10.1007/s10120-020-01042-y.
- 14. Garg PK, Jakhetiya A, Sharma J et al. Lymphadenectomy in gastric cancer: Contentious issues. World J Gastrointest Surg 2016 April 27; 8(4): 294-300.
- 15. Xu J, Bian YH, Jin X et al. Prognostic assessment of different metastatic lymph node staging methods for gastric cancer after D2 resection. World J Gastroenterol 2013 March 28; 19(12): 1975-1983.
- 16. Shi RI, Chen Q, Ding JB et al. Increased number of negative lymph nodes is associated with improved survival outcome in node positive gastric cancer following radical gastrectomy. 2016 www.impactjournals.com/oncotarget/Oncotarget, Vol. 7, No. 23.
- 17. Gu P, Deng J, Sun Z. Superiority of log odds of positive lymph nodes (LODDS) for prognostic prediction after gastric cancer surgery: a multiinstitutional analysis of 7620 patients in China 2020; Surgery Today https://doi.org/10.1007/s00595-020-02091-7.
- 18. Eom BW, Joo J, Kim YW et al. Improved survival after adding dissection of the superior mesenteric vein lymph node (14v) to standard D2 gastrectomy for advanced distal gastric cancer. Surgery 2014; 155: 408-416.
- 19. De Manzoni G, Verlato G, Bencivenga M et al. Impact of super-extended lymphadenectomy on relapse in advanced gastric cancer. Eur J Surg Oncol 2015; 41: 534-540.
- 20. Szczepanik AM, Paszko A, Szura M. Alternative staging of regional lymph nodes in gastric cancer. Gastroenterology Rev 2016; 11 (3): 145–149.
- 21. Bilici A, Selcukbiricik F, Seker M. Prognostic Significance of Metastatic Lymph Node Ratio in Patients with pN3 Gastric Cancer Who Underwent Curative Gastrectomy. Oncol Res Treat 2019;42:204–211.